tenofovir disoproxil fumarate TDF
Selected indexed studies
- From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B. (Expert Rev Anti Infect Ther, 2024) [PMID:39360716]
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (J Hepatol, 2018) [PMID:29756595]
- Tenofovir alafenamide fumarate. (Antivir Ther, 2022) [PMID:35499175]
_Worker-drafted node — pending editorial review._
Connections
tenofovir disoproxil fumarate TDF is a side effect of
Sources
- Tenofovir alafenamide fumarate. (2022) pubmed
- Is tenofovir disoproxil fumarate associated with weight loss? (2021) pubmed
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (2018) pubmed
- Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). (2016) pubmed
- From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B. (2024) pubmed
- Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B. (2024) pubmed
- Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity. (2023) pubmed
- Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer. (2024) pubmed
- Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study. (2024) pubmed
- Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen. (2020) pubmed